

[wherein R^1 is carboxy or protected carboxy,


R^2 is aryl which may optionally have one or more suitable substituents,

R^3 is aryl which may optionally have one or more suitable substituents,


A^1 is lower alkylene,

A^2 is a single bond or lower alkylene and

$-Q^1-$ is




(in which



represents cyclo(lower)alkane or cyclo(lower)alkene, which respectively may optionally have one or more suitable substituents)].

4. (Amended) A pharmaceutical composition as claimed in Claim 1, wherein the nonprostanoid prostaglandin I₂ agonist is a compound of the following general formula (II) or a pharmaceutically acceptable salt thereof:



[wherein R⁴ is carboxy or protected carboxy,

R⁵ is hydrogen, hydroxy or protected hydroxy,


R⁶ is hydrogen, hydroxy, protected hydroxy, lower alkyl or halogen,

R⁷ is hydrogen or halogen,


A⁵ is lower alkylene,

A⁶ is a single bond or lower alkylene and


-R⁸ is




(in which R⁹ is mono(or di or tri)aryl(lower)alkyl and Z is N or CH) or




(in which -A⁷- is



(in which R^{12} is hydrogen or lower alkyl), Q^2 is N or CH, R^{10} is aryl and R^{11} is aryl), and



5. (Amended) A pharmaceutical composition as claimed in Claim 1, wherein the nonprostanoid prostaglandin I_2 agonist is a compound of the following general formula (III) or a pharmaceutically acceptable salt thereof




[wherein R^{13} is carboxy or protected carboxy,

R^{14} is aryl which may optionally have one or more suitable substituents,




R^{15} is aryl which may optionally have one or more suitable substituents,

R^{16} is hydrogen, lower alkyl, hydroxy or aryl,


A^8 is lower alkylene,




is




or



$-A^{10}-$ is



(in which $-A^{11}-$ is a single bond, $-\text{CH}_2-$ or $-\text{CO}-$,



represents cyclo(C5-C8)alkene, cyclo(C7-C8)alkane, bicycloheptane, bicycloheptene, tetrahydrofuran, tetrahydrothiophene, azetidine, pyrrolidine or piperidine, which respectively may optionally have one or more suitable substituents) or $-X-A^{13}-$ (in which $-X-$ is $-\text{O}-$, $-\text{S}-$, or $-\text{N}(\text{R}^{17})-$ (R^{17} being hydrogen, lower alkyl or acyl) and A^{13} is lower alkylene which may optionally have one or more suitable substituents) and n is 0 or 1].

6. (Amended) A pharmaceutical composition as claimed in Claim 1, wherein the nonprostanoid prostaglandin I_2 agonist is

(1) [3-[[[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl]phenoxy]acetic acid,

(2) [3-[[[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl]methyl]phenoxy]acetic acid,


(3) [(2R)-5-(carboxymethoxy)-2-hydroxy-1,2,3,4-tetrahydronaphth-2-yl]methyl]N,N-diphenylcarbamate,

(4) (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-carboxymethoxy-1,2,3,4-tetrahydronaphthalene or

(5) [3-[[[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid, or a pharmaceutically acceptable salt thereof.

Please add the following new Claims 9-12:

9. (New) A pharmaceutical composition as claimed in Claim 2, wherein the nonprostanoid prostaglandin I₂ agonist is a compound of the following general formula (I) or a pharmaceutically acceptable salt thereof:



[wherein R^1 is carboxy or protected carboxy,


R^2 is aryl which may optionally have one or more suitable substituents,

R^3 is aryl which may optionally have one or more suitable substituents,

A^1 is lower alkylene,

A^2 is a single bond or lower alkylene and

$-Q^1-$ is




(in which



represents cyclo(lower)alkane or cyclo(lower)alkene, which respectively may optionally have one or more suitable substituents)].

10. (New) A pharmaceutical composition as claimed in Claim 2, wherein the nonprostanoid prostaglandin I_2 agonist is a compound of the following general formula (II) or a pharmaceutically acceptable salt thereof:



[wherein R^4 is carboxy or protected carboxy,

R^5 is hydrogen, hydroxy or protected hydroxy,


R^6 is hydrogen, hydroxy, protected hydroxy, lower alkyl or halogen,

R⁷ is hydrogen or halogen,


A⁵ is lower alkylene,

A⁶ is a single bond or lower alkylene and


-R⁸ is




(in which R⁹ is mono(or di or tri)aryl(lower)alkyl and Z is N or CH) or




(in which -A⁷- is



(in which R¹² is hydrogen or lower alkyl), Q² is N or CH, R¹⁰ is aryl and R¹¹ is aryl), and



11. (New) A pharmaceutical composition as claimed in Claim 2, wherein the nonprostanoid prostaglandin I₂ agonist is a compound of the following general formula (III) or a pharmaceutically acceptable salt thereof




[wherein R¹³ is carboxy or protected carboxy,

R¹⁴ is aryl which may optionally have one or more suitable substituents,


R¹⁵ is aryl which may optionally have one or more suitable substituents,

R¹⁶ is hydrogen, lower alkyl, hydroxy or aryl,


A⁸ is lower alkylene,



-A¹⁰- is



(in which -A¹¹- is a single bond, -CH₂- or -CO-,



represents cyclo(C5-C8)alkene, cyclo(C7-C8)alkane, bicycloheptane, bicycloheptene, tetrahydrofuran, tetrahydrothiophene, azetidine, pyrrolidine or piperidine, which respectively may optionally have one or more suitable substituents) or $-X-A^{13}-$ (in which $-X-$ is $-O-$, $-S-$, or $-N(R^{17})-$ (R^{17} being hydrogen, lower alkyl or acyl) and A^{13} is lower alkylene which may optionally have one or more suitable substituents) and n is 0 or 1].

12. (New) A pharmaceutical composition as claimed in Claim 2, wherein the nonprostanoid prostaglandin I_2 agonist is

- (1) [3-[[[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclohexen-1-yl]methyl]phenoxy]acetic acid,
- (2) [3-[[[(1S)-2-(4,5-diphenyloxazol-2-yl)-2-cyclopenten-1-yl]methyl]phenoxy]acetic acid,
- (3) [(2R)-5-(carboxymethoxy)-2-hydroxy-1,2,3,4-tetrahydronaphth-2-yl]methyl]N,N-diphenylcarbamate,
- (4) (1R)-1-[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]-5-carboxymethoxy-1,2,3,4-tetrahydronaphthalene or
- (5) [3-[[[(2R)-2-(4,5-diphenyloxazol-2-yl)pyrrolidin-1-yl]methyl]phenoxy]acetic acid, or a pharmaceutically acceptable salt thereof.